LoginSignup
Moderna logo

Moderna Stock

StockStock
ISIN: US60770K1079
Ticker: MRNA
US60770K1079
MRNA

Price

Frequently asked questions

What is Moderna's market capitalization?

The market capitalization of Moderna is $16.45B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.

What is the Earnings Per Share (EPS) for Moderna?

Moderna's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$5.806. EPS indicates the company's profitability on a per-share basis.

What are the analyst ratings and target price for Moderna's stock?

Currently, 23 analysts cover Moderna's stock, with a consensus target price of $146.11. Analyst ratings provide insights into the stock's expected performance.

What is Moderna's revenue over the trailing twelve months?

Over the trailing twelve months, Moderna reported a revenue of $5.08B.

What is the EBITDA for Moderna?

Moderna's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$1.80B. EBITDA measures the company's overall financial performance.

What is the free cash flow of Moderna?

Moderna has a free cash flow of -$3.96B. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.

What is the 5-year beta of Moderna's stock?

The 5-year beta for Moderna is 1.59. A beta value indicates the stock's volatility relative to the market; a beta greater than 1 means higher volatility.

How many employees does Moderna have, and what sector and industry does it belong to?

Moderna employs approximately 5,600 people. It operates in the Health Care sector, specifically within the Biotechnology & Drugs industry.

What is the free float of Moderna's shares?

The free float of Moderna is 348.22M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap

 $16.45B

5Y beta

 1.59

EPS (TTM)

 -$5.806

Free Float

 348.22M

Revenue (TTM)

 $5.08B

EBITDA (TTM)

 -$1.80B

Free Cashflow (TTM)

 -$3.96B

Pricing

1D span
$41.55$44.13
52W span
$42.25$170.47

Analyst Ratings

The price target is $146.11 and the stock is covered by 23 analysts.

Buy

10

Hold

10

Sell

3

Information

Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases, independently and with its strategic collaborators. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. Its diverse development pipeline consists of 45 therapeutic and vaccine programs, nine of which are in late-stage development. Its products include COVID-19 vaccines (mRNA-1273/Spikevax, next-generation mRNA-1283), RSV vaccine (mRNA-1345), Seasonal influenza vaccines (mRNA-1010, mRNA-1011, mRNA-1012, mRNA-1020 and mRNA-1030), Combination vaccines (mRNA-1083, mRNA-1230, mRNA-1045 and mRNA-1365), CMV vaccine (mRNA-1647), EBV vaccine (mRNA-1189 and mRNA-1195) and others.

5,600

Biotechnology & Drugs

Health Care

Identifier

ISIN

US60770K1079

Primary Ticker

MRNA

Knockouts

Join the conversation
Sign upLogin